Pharma News
23 Nov 2025 to 29 Nov 2025
Nov 29, 2025
High Court refuses bail to pharmaceutical dealer involved in drug cartel case, according to DrugsControl Media Services.
The High Court of Jammu & Kashmir and Ladakh has denied bail to Garv Bhambri, a pharmaceutical drug license holder, implicated in a nationwide narcotics trafficking network disguised as legitimate medicine manufacturing.
Nov 29, 2025
CDSCO Publishes Detailed Risk Classification Categories for Interventional Radiology
The Central Drugs Standard Control Organisation (CDSCO) has released comprehensive risk classification lists for interventional radiology, radiotherapy, and Class A medical devices in India. This initiative aims to standardize medical device regulations and enhance patient safety across the country.
Nov 29, 2025
Organizations Investing in Multinational Pharma Companies' Assets During Market Lows - 36氪
Multinational pharmaceutical companies, including Bristol Myers Squibb and Bayer, are divesting their businesses in China, selling assets to investment firms like Hillhouse Capital and Sequoia China. This shift is driven by profit pressures from national procurement policies. Companies aim to focus on innovative drugs while investment institutions leverage their resources to optimize mature assets, reshaping the competitive landscape in China's pharmaceutical industry.
Nov 29, 2025
Nationwide Operation Uncovers Extensive Network Redirecting Codeine Cough Syrups and ...
India has intensified its crackdown on the illicit diversion of prescription drugs, particularly codeine-laced cough syrups, through coordinated raids and arrests. The operation targets a vast network involved in the abuse of these substances, with actions taken under the Gangster Act against repeat offenders.
Nov 29, 2025
Drug Manufacturers Explore Shifting Focus from Television Advertising to Digital Platforms
Pharmaceutical companies are considering reducing TV advertising due to the rise of digital platforms and changing consumer behaviors. A recent report indicates that this shift could impact consumer awareness of medications and the advertising landscape, as companies explore alternatives like social media and online video. Regulatory scrutiny on direct-to-consumer advertising is also influencing these decisions.
Nov 29, 2025
Uttar Pradesh Enforces Stricter Regulations on Drug Licenses: Prohibition of Stores in Residential Areas, Geotagging Required...
The Uttar Pradesh Food Safety and Drug Administration (FSDA) has implemented strict new regulations for drug licenses, prohibiting pharmacies in residential buildings and requiring geotagged photos for compliance. This initiative aims to curb the illegal trade and misuse of narcotic drugs in the region.
Nov 28, 2025
Activists warn that regulatory and patent obstacles could hinder access to a new drug for HIV prevention.
Healthcare activists warn that regulatory delays and patent barriers threaten access to lenacapavir, a new long-acting HIV prevention drug developed by Gilead Sciences, marketed as Sunlenca and Yeztugo. They emphasize the need for a clinical trial waiver in India to facilitate affordable generics and ensure timely access for marginalized communities, as global HIV infection rates remain stagnant.
Nov 28, 2025
Research Reveals Targeting TBK1/IKKε as a Method to Boost Immune Cell Tumor Destruction
A recent study has revealed that inhibiting TBK1/IKKε can enhance immune cell-mediated tumor killing by sensitizing tumors to immune attacks. The research highlights the role of TBK1 and IKKε in regulating RIPK1 phosphorylation, suggesting that disrupting this pathway may improve cancer immunotherapy strategies. Further investigation could lead to new therapeutic approaches for cancer treatment.
Nov 28, 2025
Indians face barriers to affordable HIV medication as regulatory authorities decline to exempt local trials.
About 25 lakh Indians with HIV could benefit from a twice-yearly lenacapavir PrEP injection, priced at $40 annually, but local trials are required by the CDSCO. Four Indian manufacturers, including Dr Reddy's and Hetero, were licensed to produce lenacapavir, yet the CDSCO denied a waiver for local trials, citing insufficient data on the Indian population.
Nov 28, 2025
Korean biotech stocks increase amid excitement over domestic Mounjaro manufacturing.
Eli Lilly's weight-loss drug Mounjaro may soon be produced in Korea, boosting shares of Peptron by over 10%. Peptron plans a new plant in Cheongju, while SK Pharmteco is expanding its capabilities to produce active pharmaceutical ingredients for Mounjaro. Both companies are poised for significant growth, with potential contracts worth up to 2 trillion won.
Nov 28, 2025
A new generation of weight-loss medications, including an advanced version of Ozempic, is on the horizon.
Eli Lilly and Novo Nordisk are advancing next-generation GLP-1 weight-loss treatments, including Lilly's retatrutide and CagriSema, which target multiple hormones for enhanced weight loss. Both companies are also developing oral alternatives, with Lilly's orforglipron and Novo Nordisk's semaglutide pill expected to launch by 2026. These innovations aim to improve accessibility and effectiveness in obesity treatment.
Nov 28, 2025
New research shows weight-loss medication does not lower Alzheimer's risk - The Conversation
Recent studies reveal that semaglutide, the active ingredient in weight-loss drugs Ozempic and Wegovy, does not slow cognitive decline in early-stage Alzheimer’s patients. Trials involving nearly 3,800 participants showed no significant improvement in memory or daily functioning compared to a placebo. Following these results, Novo Nordisk has halted plans to extend the study, leading to a sharp decline in its share price.
Nov 28, 2025
AbbVie Receives Canadian Approval Recommendations for Major Ulcerative Colitis Treatment
AbbVie Inc. announced that Skyrizi (risankizumab) received positive reimbursement recommendations from Canada’s Drug Agency for ulcerative colitis, following successful phase 3 trials. The drug is recommended for adults with moderate to severe cases who have not responded to other treatments. AbbVie has also signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance regarding Skyrizi.
Nov 28, 2025
JNJ's Oncology Progress Accelerates in Pursuit of $50 Billion Target by 2030 - TradingView
Johnson & Johnson (JNJ) reported a 20.6% increase in oncology sales, reaching $18.52 billion, driven by drugs like Darzalex and Erleada. J&J aims for $50 billion in oncology sales by 2030, bolstered by new drugs such as Inlexzoh and Rybrevant. The company also plans to acquire Halda Therapeutics for $3.05 billion to enhance its oncology pipeline.
Nov 28, 2025
Novo Nordisk Sees Gains Due to IRA Pricing Support - Independent Workers
Novo Nordisk shares surged after news that U.S. price cuts for its diabetes and obesity drugs, Ozempic and Wegovy, under the Inflation Reduction Act would be less severe than anticipated. This eased concerns about revenue pressure from mandatory discounts on semaglutide, the active ingredient. Investors remain cautious about future policy impacts and competition from Eli Lilly.
Nov 28, 2025
Methods for Examining Pharmaceutical Oligopolies
At the 14th Global Investigative Journalism Conference, journalist Fabiola Torres highlighted the oligopoly in the insulin market, dominated by Novo Nordisk, Eli Lilly, and Sanofi, which keeps prices high and access limited in Peru. She emphasized the need for investigative journalism to expose the structural barriers that prevent affordable access to essential medicines, impacting patients' lives and health outcomes.
Nov 28, 2025
Major pharmaceutical companies oppose compounded weight-loss medications in Brazil.
Brazil's Federal Police have launched an operation against compounding pharmacies producing unauthorized versions of weight-loss injections based on GLP-1 analogues, specifically semaglutide and tirzepatide, patented by Novo Nordisk and Eli Lilly. Medical associations warn of health risks from these compounded drugs, which lack regulatory oversight and clinical studies, amid rising demand due to shortages of approved medications like Mounjaro and Ozempic.
Nov 27, 2025
Novo Nordisk Requests Expedited Approval from FDA for Increased Dosage of Wegovy - Yahoo Finance
Novo Nordisk (NVO) has submitted a regulatory filing to the FDA for a 7.2 mg dose of its obesity drug, Wegovy (injectable semaglutide), claiming it offers greater weight loss potential. The filing seeks an expedited review through the CNPV pilot program. Data from the STEP UP study supports the efficacy of the higher dose.
Nov 27, 2025
More than 168 pharmaceutical samples identified as substandard by Pharma Hub in the past two and a half years.
Over the past two and a half years, 168 drug samples from a major pharmaceutical manufacturing hub in Solan have been declared "Not of Standard Quality" or "misbranded," prompting increased regulatory scrutiny. This situation has raised concerns about the quality control measures in place within the industry.
Nov 27, 2025
DCC emphasizes the importance of consistent application of drug standards across the country.
The Drugs Consultative Committee (DCC) has emphasized the urgent need for uniform implementation of drug standards across India, citing concerns over inconsistent adherence in some states and low conviction rates due to delays. The DCC's call aims to enhance drug safety and regulatory compliance nationwide.
Nov 27, 2025
Novo Nordisk Requests Expedited Approval from FDA for Increased Dosage of Wegovy - Finviz
Novo Nordisk (NVO) has submitted a regulatory filing to the FDA for a 7.2 mg dose of its obesity drug, Wegovy (injectable semaglutide), claiming it offers greater weight loss potential. The company seeks an expedited review through the CNPV pilot program. Data from the STEP UP study supports the filing, showing significant weight loss compared to lower doses and placebo.
Nov 27, 2025
Can Opdivo and Opdivo Qvantig Propel BMY's Revenue Growth? - sharewise
Bristol Myers Squibb (BMY) reported a 7% increase in Opdivo sales, reaching $2.5 billion in Q3, driven by strong demand and label expansions. The recent approval of Opdivo Qvantig injection contributed $67 million in sales. Despite competition from Merck's Keytruda and Roche's Tecentriq, BMY expects global Opdivo sales to grow in the high single to low double-digit range by 2025.
Nov 27, 2025
Analysis of Section 3(i) and Drug Composition Assertions: Insights on Medilabo RFP Inc v Controller ...
The Delhi High Court's ruling in Medilabo RFP Inc v. Controller of Patents clarifies that pharmaceutical compositions, such as those containing rifampicin and resveratrol for neurodegenerative diseases, are patentable under Section 3(i) of the Patents Act. The court emphasized the need for patent controllers to consider all objections and amended claims, reinforcing the distinction between product claims and treatment methods.
Nov 27, 2025
JAMIE CARR: Eli Lilly experiences a surge due to increased medication use - Financial Mail
Eli Lilly has achieved a market cap exceeding $1 trillion, becoming the first pharmaceutical company in this elite club, driven by the success of its drugs Zepbound and Mounjaro, which generated nearly $19 billion in sales in 2025. The company plans to invest heavily in synthetic drug production and is set to launch a weight-loss pill.
Nov 27, 2025
Medicare Reduces Prescription Costs: CMS Reveals 44% Savings in Latest Round of IRA Negotiations
The Centers for Medicare & Medicaid Services announced significant price cuts for 15 high-cost prescription drugs, including Novo Nordisk’s Ozempic and Wegovy, which will see a 71% reduction. Pfizer’s Ibrance will be halved in price. These changes, effective January 2027, aim to save taxpayers $12 billion and mark a historic shift in U.S. drug pricing policy.
Nov 27, 2025
Eli Lilly: Could It Be the Next Company to Split Its Stock? - AOL.com
Eli Lilly's stock has surged 200% over the past three years, driven by its successful weight loss drugs, Mounjaro and Zepbound. Currently trading around $1,000, analysts speculate a potential stock split could enhance accessibility for investors. Despite its impressive growth, Eli Lilly was not included in a recent list of top stock recommendations by The Motley Fool.
Nov 27, 2025
AstraZeneca vs. Merck: Which Cancer Treatment Leader Holds the Advantage? - Yahoo Finance
Merck & Co. (MRK) is set to enhance its portfolio with the $9.2 billion acquisition of Cidara Therapeutics (CDTX), adding the antiviral candidate CD388. Despite strong sales from Keytruda, Merck faces challenges from declining products and competition. Meanwhile, AstraZeneca (AZN) aims for $80 billion in revenue by 2030, bolstered by a robust pipeline and recent drug launches.
Nov 27, 2025
NGOs warn that regulatory and intellectual property obstacles may restrict access to affordable lenacapivir.
Indian generic manufacturers are poised to supply lenacapavir, a groundbreaking HIV prevention drug, at affordable prices. However, regulatory delays and Gilead's patent filings threaten global access, particularly for marginalized communities. Health advocates stress the urgent need for policy changes to ensure lenacapavir's availability, as it has shown nearly 100% effectiveness in preventing HIV.
Nov 27, 2025
Novo Nordisk aims for expedited FDA authorization of an increased dosage of Wegovy - Longevity.Technology
Novo Nordisk has submitted a supplemental New Drug Application to the FDA for a higher-dose 7.2 mg version of its obesity drug Wegovy, nearly triple the current dose. The application is fast-tracked under the FDA’s new Commissioner’s National Priority Voucher program, aiming for a decision in one to two months. Clinical trials indicate significant weight loss potential with the new formulation.
Nov 27, 2025
Can Opdivo and Opdivo Qvantig Propel BMY's Revenue Growth? - Finviz
Bristol Myers Squibb (BMY) reported strong sales for its oncology drug Opdivo, generating approximately $2.5 billion in Q3, driven by demand in colorectal and lung cancers. The recent approval of Opdivo Qvantig injection further supports growth. However, BMY faces competition from Merck's Keytruda and Roche's Tecentriq. BMY shares have declined 12.9% year-to-date, trading at a discount compared to the industry.
Nov 26, 2025
Civil society organizations are opposing government agencies' consideration of data exclusivity in pharmaceutical regulations.
Patient groups and public health advocates are urging the Indian government to reject proposed data exclusivity provisions, arguing it would extend monopolies and inflate drug prices. They cite the case of risdiplam, priced at Rs.6.2 lakh by Roche, with a generic version available for Rs.15,900. Critics warn that data exclusivity could jeopardize India's generic drug industry and access to affordable medicines.
Nov 26, 2025
Wyden's Remarks on Trump's Declaration Regarding Medicare Drug Price Negotiations
Senate Finance Committee Ranking Member Ron Wyden criticized the Trump administration's announcement of Medicare-negotiated prices for 15 expensive prescription drugs, emphasizing that Democrats fought for lower costs for seniors. He highlighted the impact of Republican actions that delayed negotiations on costly drugs, particularly cancer treatments like Keytruda, undermining efforts to reduce health costs for older Americans.
Nov 26, 2025
15 key medications, such as Ozempic and cancer treatments, set to see price reductions.
The US government will lower prices for 15 widely used prescription drugs, including Ozempic and cancer treatments like Xtandi and Ibrance, starting January 2027. This initiative, part of the Inflation Reduction Act, aims to save taxpayers $12 billion and provide relief for millions of Medicare patients. The move faces criticism from drugmakers over potential impacts on innovation.
Nov 26, 2025
Ozempic and Wegovy: Insights from LAist
The federal government announced a 71% discount on Ozempic, Wegovy, and Rybelsus as part of Medicare's drug price negotiations, effective in 2027. The negotiations, influenced by the Inflation Reduction Act, aim to lower costs for seniors. Novo Nordisk, the manufacturer, expressed concerns about the impact of government price setting. AARP praised the negotiations as a significant step towards affordable medication.
Nov 26, 2025
Ozempic tablet does not reduce the progression of Alzheimer's disease - USA Today
Novo Nordisk has decided not to pursue Alzheimer's treatment with its diabetes and weight-loss drugs, Ozempic and Wegovy, after studies showed semaglutide failed to slow cognitive decline in early-stage Alzheimer's patients. The company will present further details at an upcoming Alzheimer's conference in San Diego, with researchers hoping to find insights for future treatments.
Nov 26, 2025
Trump's GLP-1 Agreement May Reduce Telehealth Compounding, Yet Providers Remain Flexible
The Trump administration's agreement to reduce costs for Lilly and Novo Nordisk's GLP-1 drugs may influence telehealth companies to favor brand-name versions over compounded alternatives, according to experts from Inside Health Policy.
Nov 26, 2025
Medicare has successfully negotiated reduced prices for 15 medications, achieving a 71% discount on Ozempic and Wegovy.
Medicare has negotiated lower prices for 15 drugs, including a 71% discount on Novo Nordisk's Ozempic and Wegovy, effective in 2027. The negotiations, part of the Inflation Reduction Act, aim to reduce healthcare costs for seniors. The new prices could save Medicare $12 billion, with AARP praising the move as a significant step towards affordable medications.
Nov 26, 2025
Study: Despite Novo Nordisk's setback, researchers explore GLP-1s for Alzheimer's prevention.
Novo Nordisk's Alzheimer’s trials for Rybelsus, a semaglutide-based drug, failed to delay cognitive decline in early-stage patients. However, some biological improvements were noted, prompting discussions on testing GLP-1 drugs for prevention in at-risk individuals. Experts emphasize the need for future trials to explore potential benefits of GLP-1s, including those from rival Eli Lilly's Zepbound and Mounjaro.
Nov 26, 2025
CMS establishes Medicare pricing for Wegovy, Trelegy, and 13 additional medications for 2027 | BioPharma Dive
Medicare will significantly reduce payments for 15 drugs in 2027, including Novo Nordisk's semaglutide (Wegovy, Ozempic) and Pfizer's Ibrance, following price negotiations mandated by the Inflation Reduction Act. The changes could save $12 billion in spending and lower out-of-pocket costs for beneficiaries. Future negotiations will target an additional 15 high-expenditure drugs in 2026.
Nov 26, 2025
Medicare reveals reductions in prices for 15 medications, featuring Ozempic - AOL.com
The Centers for Medicare and Medicaid Services announced significant price cuts on 15 prescription drugs, including Ozempic and Wegovy, under the Medicare drug price negotiation program. The negotiated prices will save taxpayers $12 billion and Medicare enrollees $685 million in out-of-pocket costs by 2027. The cuts reflect ongoing efforts to make medications more affordable for Americans.
Nov 26, 2025
Eli Lilly: Could It Be the Next Company to Split Its Stock? - The Globe and Mail
Eli Lilly's stock has surged 200% over the past three years, driven by its successful weight loss drugs, Mounjaro and Zepbound. Currently trading around $1,000, analysts speculate a potential stock split could enhance accessibility for investors. Despite its impressive growth, Eli Lilly was not included in a recent list of top stock recommendations by The Motley Fool.
Nov 26, 2025
Medicare to Reduce Drug Prices by as Much as 85% for Treatments Related to Weight Loss, Cancer, Asthma, and Other Conditions
Medicare beneficiaries will see up to 85% savings on 15 blockbuster drugs, including semaglutide (Ozempic, Rybelsus, Wegovy) and palbociclib (Ibrance), starting in 2027, according to CMS. The negotiated prices, part of the Inflation Reduction Act, could save seniors $685 million in out-of-pocket costs that year. The first round of negotiated prices will begin in January 2026.
Nov 26, 2025
Prestige Biopharma and Biosidus Sign Exclusive Licensing Deal for Tuznue ... - The Hindu
Prestige Biopharma has signed an exclusive license and supply agreement with Biosidus for the commercialization of Tuznue® (trastuzumab) in Latin America, including Argentina, Mexico, Bolivia, and Paraguay. Tuznue® is a biosimilar to Herceptin® and is approved for breast and gastric cancer treatment. This partnership aims to enhance access to affordable biotechnological medicines in the region.
Nov 26, 2025
The Next Phase of Korea's ADC Conflict: Success Depends on Surmounting Opposition
Korean biotech firms, including Samsung Epis Holdings and Celltrion, are advancing in the antibody-drug conjugate (ADC) market, focusing on overcoming resistance to Enhertu, a leading HER2-targeted ADC. With 24% resistance within a year, companies are developing new strategies and payloads, such as Celltrion's CT-P70 and LegoChem's LCB14, to enhance efficacy against various cancers.
Nov 26, 2025
Japanese Authorities Explore Possible Enhancements to Patent Linkage Framework for Generic Drugs
The Japanese Ministry of Health, Labour and Welfare (MHLW) is set to trial a new expert panel system to assess patent infringement risks for generic products. This initiative aims to enhance the patent linkage system and reduce post-approval disputes. The MHLW is currently assembling experts and will publish further details soon. Brand companies must continue submitting relevant patent lists.
Nov 26, 2025
Jharkhand High Court rules that cough syrup sales require a doctor's prescription.
The Jharkhand High Court has ruled that cough syrup and other medicines cannot be sold without a doctor's prescription. This decision follows a public interest litigation filed by activist Sunil Kumar Mahto, urging the state government to enforce stricter regulations on the sale and use of these medications.
Nov 26, 2025
Activists argue that data exclusivity will prolong pharmaceutical monopolies and hinder access to low-cost medications.
Healthcare activists in India are opposing the Central Drugs Standard Control Organisation's consideration of data exclusivity provisions, warning it could delay access to lifesaving generic drugs and undermine India's status as a leading supplier. They argue that such provisions would extend pharmaceutical monopolies, jeopardizing affordable medicines like Roche's risdiplam, which is now available generically at ₹12,000.
Nov 26, 2025
Aspire BioPharma Welcomes Dr. Jaroszeski, Creator of 34 Patents | ASBP Stock Update
Aspire Biopharma Holdings, Inc. has appointed Dr. Mark J. Jaroszeski, a renowned expert in DNA and drug delivery, to its scientific team. Dr. Jaroszeski's expertise will enhance Aspire's patent-pending sublingual delivery technology, aimed at improving drug effectiveness and reducing side effects. His extensive experience includes over 100 clinical trials and 34 U.S. patents.
Nov 26, 2025
Amgen wins against Sanofi in the UPC Court of Appeal, represented by Brinkhof and Bardehle.
The European Patent Office upheld Amgen's patent EP 3 666 797 for its cholesterol drug Repatha, despite a previous invalidation by the UPC central division. This ruling allows Amgen to proceed with its infringement case against Sanofi's Praluent. The ongoing legal battle highlights significant financial stakes, with costs estimated at €100 million for each appeal.
Nov 26, 2025
Avantor awarded the 2025 Edison Patent Award for its eco-friendly viral inactivation technology.
Avantor, Inc. and Amgen have been awarded the 2025 Edison Patent Award for their innovative biodegradable detergent that enhances viral inactivation in biomanufacturing. This technology improves protein integrity and process yield, addressing key industry challenges in producing monoclonal antibodies, vaccines, and gene therapies. The collaboration highlights the importance of sustainable practices in biomanufacturing.
Nov 26, 2025
The misuse of patents and its impact on access to essential medications | Perspective - The Tennessean
Aundrea Gomez highlights the struggles her husband faces while battling leukemia, relying on a costly drug exceeding $30,000 monthly. She criticizes Big Pharma for patent abuse, which prevents access to more affordable and less harmful treatment options.
Nov 26, 2025
The misuse of patents and its impact on accessibility to essential medications - The Leaf-Chronicle
Aundrea Gomez highlights the struggles her husband faces while battling leukemia, relying on a costly drug exceeding $30,000 monthly. She criticizes Big Pharma for patent abuse, which limits access to more affordable and less harmful treatment options.
Nov 26, 2025
Impact of New Trade Agreement on Kenyans' Access to Low-Cost Medications - TNX Africa
Kenya's Pharmaceutical Society, led by Dr. Wairimu Mbogo, warns that new clauses in the Comprehensive Economic Partnership Agreement (CEPA) could extend data exclusivity for multinational drug companies by five years, hindering access to affordable generics and local manufacturing. Experts emphasize the need to prioritize public health and maintain reservations in the agreement to protect patient care and safety.
Nov 26, 2025
CDSCO reports that India's pharmaceutical industry is shifting from producing generic medications to developing innovative drugs.
India's pharmaceutical sector is shifting from generics to innovative biologics, as noted by the CDSCO. Dr. R. Chandrashekar highlighted government reforms, including streamlined approvals and a ₹1,00,000 crore Hospital Finance scheme, to boost R&D. Experts at the CPHI & PMEC India Expo urged a focus on value-driven innovations like peptides and biosimilars.
Nov 25, 2025
OPINION: Protect vital research funding in Ohio from Congressional cuts
The Senate Judiciary Committee has advanced several bills, including the Affordable Prescriptions for Patients Act and the Drug Competition Enhancement Act, which may hinder biopharmaceutical innovation. Critics argue these bills misunderstand the patent system's role in drug development, potentially delaying market entry for generics and discouraging beneficial drug improvements. Ohio's life sciences sector, vital for investment, could be adversely affected.
Nov 25, 2025
MFDS Publishes Patent Details for Medications Approaching Expiration of Data Protection Terms
The Ministry of Food and Drug Safety announced it will release patent information for 507 products, including fexuprazan preparations and botulinum preparations, whose data protection and re-examination periods expire within three years. This initiative aims to support the development of domestic generic drugs and enhance market strategies for companies in Korea.
Nov 25, 2025
Blacksmith Medicines secures European patent for antibacterial agents targeting LpxC.
Blacksmith Medicines, Inc. announced that the European Patent Office intends to grant a patent for FG-960, the active form of FG-2101, an antibiotic targeting LpxC in Gram-negative bacteria. This follows similar patents in the U.S., China, and Japan. CEO Zachary Zimmerman highlighted FG-2101's potential against resistant pathogens, emphasizing Blacksmith's innovative platform for metalloenzyme-targeted therapeutics.
Nov 25, 2025
Lilly Transforms the Pharmaceutical Mega-Blockbuster Landscape - BioSpace
Eli Lilly's tirzepatide franchise, including Mounjaro and Zepbound, has surpassed Merck's Keytruda in sales for the first time, with projections reaching $101 billion. Lilly's rapid growth, driven by effective marketing and superior efficacy in trials against Novo Nordisk's semaglutide, positions it as a leader in the diabetes and weight loss market.
Nov 25, 2025
The Department of Pharmaceuticals is considering exempting an additional 84 medications from public procurement regulations that limit international bidding.
The Department of Pharmaceuticals (DoP) is contemplating exempting 84 additional drug formulations from public procurement rules that limit global tenders. This includes patented and proprietary products, as well as medicines that have not yet been launched.
Nov 25, 2025
BofA Anticipates Favorable Prospects for Novartis and GSK Due to Upcoming Developments - Meyka
Bank of America has upgraded its outlook on Novartis and GSK, highlighting significant upcoming milestones in their research pipelines. Novartis is focusing on oncology and gene therapy, while GSK is capitalizing on strong vaccine demand. Both companies are poised for growth, but face risks from patent expirations and regulatory challenges. Investors are advised to monitor these developments closely.
Nov 25, 2025
What additional health issues are being explored for treatment with weight-loss medications? - Yahoo
Novo Nordisk's weight-loss drug semaglutide, marketed as Rybelsus, failed to slow cognitive decline in Alzheimer's patients during late-stage trials, disappointing hopes for a new market for GLP-1 medicines. This setback comes as Novo faces increasing competition in obesity and diabetes treatments, including its other products Ozempic and Wegovy.
Nov 25, 2025
Research associates GLP-1 weight-loss medications with increased weight gain during pregnancy and associated risks - India Today
A study published in JAMA reveals that women who stop GLP-1 therapies, like Mounjaro and Wegovy, upon becoming pregnant experience greater weight gain and higher pregnancy complications. The research highlights the need for careful pre-pregnancy weight management and monitoring for women using these medications, as they face increased risks of gestational diabetes and preterm delivery.
Nov 25, 2025
Vyome Names Esteemed Medical Oncologist Dr. Aditya Bardia as Senior ... - Business Wire
Vyome Holdings, Inc. has appointed Dr. Aditya Bardia as Senior Medical Advisor to guide the clinical development of its lead asset, VT-1953, aimed at treating malignant fungating wounds in cancer patients. The company targets FDA approval for VT-1953 by 2026, with promising preliminary data showing significant symptom relief and improved quality of life for patients.
Nov 25, 2025
Novo advances next-generation medication amycretin to final phase of diabetes trial following encouraging results.
Novo Nordisk reported promising mid-stage results for its obesity drug amycretin, showing significant weight loss in diabetes patients, which boosted shares by over 5%. The drug, which mimics GLP-1 and amylin, helped patients lose up to 14.5% of body weight. Analysts predict peak sales of $8 billion by 2034, as Novo aims to regain market leadership.
Nov 25, 2025
Loophole for Orphan Drugs Protects Major Medications from Price Negotiations
The One Big Beautiful Bill Act, signed into law in July 2025, exempts orphan drugs from Medicare price negotiations, potentially impacting billions in spending. Notable drugs like Merck's Keytruda and Bristol Myers Squibb's Opdivo, both oncology blockbusters, will see delayed negotiations. Analysts warn this could inflate costs for Medicare beneficiaries and taxpayers, undermining the Inflation Reduction Act's goals.
Nov 25, 2025
Coca Plant's Pharmaceutical Breakthrough: Transforming a Sacred Leaf into a Modern Medical Marvel
The coca plant (Erythroxylum coca) is gaining attention in pharmaceutical research for its therapeutic potential, particularly in treating neurological disorders, pain management, and developing nutraceuticals. Recent legal reforms in Colombia, Bolivia, and Peru are facilitating this innovation, with over 331 patent applications filed globally. Companies like Peru's ENACO and Bolivia's KOKABOL are already commercializing coca-based products, signaling a shift towards mainstream acceptance.
Nov 24, 2025
Indian and Israeli Startups Unite to Pioneeringly Innovate in Medical Device Development
India is enhancing its healthcare innovation by collaborating with Israeli startups to develop advanced medical devices, cybersecurity, and mobility solutions. This partnership aims to strengthen India's position in the global healthcare landscape.
Nov 24, 2025
Eli Lilly Achieves Milestone as the First Health Company Valued at One Trillion Dollars - pmg-ky1.com
Eli Lilly has made history by becoming the first healthcare company to reach a $1 trillion market valuation, driven by its diabetes drug Mounjaro and weight loss drug Zepbound. The company reported significant sales growth, with Mounjaro generating $6.52 billion and Zepbound $3.59 billion in Q3 2025. Eli Lilly plans to release an oral version of Zepbound next year.
Nov 24, 2025
Novo Nordisk's Alzheimer's medication trials fall short, dealing a setback to the weight-loss powerhouse - TradingView
Novo Nordisk's Alzheimer's trials for its oral semaglutide drug, Rybelsus, have failed to slow cognitive decline, leading to a 12% drop in the company's shares. The trials, involving 3,808 patients, were seen as a potential breakthrough for GLP-1 drugs. Analysts remain skeptical about Novo's Alzheimer's ambitions, while Eli Lilly's shares rose following the news.
Nov 24, 2025
Novo Nordisk's Alzheimer's medication trials fall short, dealing a setback to the weight-loss powerhouse - Yahoo Finance
Novo Nordisk's trials of its oral semaglutide drug, Rybelsus, for Alzheimer's disease have failed to show efficacy in slowing cognitive decline, leading to a significant drop in the company's shares. The disappointing results hinder hopes for expanding the market for GLP-1 medicines. Despite the setback, the Alzheimer's Association remains committed to exploring this class of drugs further.
Nov 24, 2025
Major GLP-1 Medications for Diabetes and Weight Loss Show No Success in Alzheimer's Study
Novo Nordisk's GLP-1 drug semaglutide, marketed as Ozempic and Wegovy, has failed to demonstrate efficacy in treating Alzheimer’s in two large trials, despite altering some biomarkers. The company announced the results on Nov. 24, halting further trials. This setback challenges the notion that targeting glucose metabolism could aid Alzheimer’s treatment, as seen with previous GLP-1 drugs.
Nov 24, 2025
Novo Nordisk shares hit a four-year low following unsatisfactory results from an Alzheimer's study.
Novo Nordisk's stock plummeted over 5% to a four-year low of $45 following clinical failures of semaglutide, the key ingredient in its drugs Ozempic and Wegovy, in Alzheimer’s trials. The company faces increased competition from Eli Lilly's Zepbound and has implemented significant price cuts, raising concerns about future growth and profitability amid regulatory pressures.
Nov 24, 2025
Pfizer Makes a Significant $6 Billion Investment in Weight-Loss Medications - Ad-hoc-news.de
Pfizer is launching a $6 billion debt offering to finance its acquisition of Metsera Inc. as it pivots into the weight-loss medication market amid looming patent expirations threatening $17 billion in annual revenue. Analysts have mixed views on this strategy, with Goldman Sachs maintaining a neutral stance and Scotiabank optimistic about potential growth. Pfizer's stock closed at $21.71, with a dividend yield of 6.9%.
Nov 24, 2025
Analysis of Leading Companies and Regional Trends in Generic Pharmaceuticals Through 2031
The generic drugs market is projected to grow significantly by 2031, featuring key players such as Teva Pharmaceutical Industries Ltd, Viatris Inc, and Dr. Reddy's Laboratories Ltd. Generic drugs, which must demonstrate bioequivalence to brand-name medications, offer lower costs and maintain the same clinical effects, entering the market post-patent expiration.
Nov 24, 2025
D.C. Court Dismisses Teva's Appeal Against Medicare Negotiation, Determining Lack of Property Interest
The U.S. District Court for the District of Columbia has upheld the Medicare Drug Price Negotiation Program, rejecting Teva Pharmaceuticals' challenge. The court ruled that Teva lacks a protected property interest in selling drugs at higher prices than Medicare's reimbursement rates. This decision supports the 2022 Inflation Reduction Act, affirming the legality of price negotiations for drugs like Teva's AUSTEDO.
Nov 24, 2025
Lawsuit claims Telix violated licensing agreement for cancer treatment Zircaix | Lawyerly
Heidelberg Pharma has filed a lawsuit against Telix, accusing the Australian company of breaching a license agreement related to the kidney cancer diagnostic drug Zircaix. The legal action highlights ongoing disputes in the pharmaceutical industry over intellectual property rights.
Nov 24, 2025
Novo Nordisk's Major Medication Does Not Hinder Alzheimer's Disease Advancement in Research Trials
Novo Nordisk announced the discontinuation of late-stage trials for Semaglutide in Alzheimer’s disease, as results did not show superiority over placebo in slowing disease progression. Despite observing improvements in Alzheimer’s biomarkers, the trials failed to demonstrate a delay in disease progression. Following the announcement, shares of Novo Nordisk fell over 9% in pre-market trading.
Nov 24, 2025
Novo Nordisk's Highly Anticipated Weight-Loss Medication Fails in Alzheimer's Study - Benzinga
Novo Nordisk A/S (NYSE:NVO) shares dropped 10.73% after the company announced that its phase 3 trials, evoke and evoke+, did not show semaglutide's superiority over placebo in slowing Alzheimer’s disease progression. Despite improvements in biomarkers, the results led to the discontinuation of a planned extension period. Full trial results will be presented at upcoming conferences.
Nov 24, 2025
Novo Nordisk's stock drops 9% following the unsuccessful results of an Alzheimer's medication trial - CNBC
Shares of Novo Nordisk fell to a four-year low after its Alzheimer's trial for semaglutide, the active ingredient in Ozempic and Wegovy, failed to meet its primary goal of slowing cognitive decline. Despite some improvements in biomarkers, the results disappointed investors, leading to a 10% drop in stock price. Rival Eli Lilly's stock rose amid the news.
Nov 24, 2025
Novo Nordisk's Ozempic Tablet Falls Short in Ambitious Alzheimer's Trial - NDTV Profit
Novo Nordisk A/S's Ozempic pill failed to slow Alzheimer's progression in two high-risk studies, leading to a 12.4% stock drop. The company will discontinue the study extension, marking a setback under CEO Mike Doustdar. Despite hopes for a transformative impact, the failure raises concerns about Novo's competitiveness in the obesity market against Eli Lilly & Co.
Nov 24, 2025
Novo Nordisk's stock drops following unsuccessful Alzheimer's trials for Ozempic pill - The Guardian
Novo Nordisk's shares fell over 10% after the company announced that the pill version of its weight-loss drug Ozempic failed to slow Alzheimer's progression in two large studies. Despite improvements in Alzheimer’s markers, the trials did not meet expectations. The company faces increased competition from Eli Lilly, which recently reached a $1 trillion market value.
Nov 24, 2025
What additional health issues are being addressed with weight-loss medications in research and trials? | 104.1 WIKY
Novo Nordisk's weight-loss drug semaglutide, marketed as Rybelsus, failed to slow cognitive decline in Alzheimer’s patients during late-stage trials, dampening prospects for expanding into the Alzheimer’s market. This setback comes as competition rises for its leading obesity and diabetes treatments, Ozempic and Wegovy, which also contain semaglutide.
Nov 24, 2025
Unexpected additional conditions that weight-loss medications may help address | The Independent
Novo Nordisk's semaglutide, marketed as Rybelsus, failed to slow cognitive decline in Alzheimer's patients during late-stage trials, marking a setback for potential Alzheimer's treatments. The drug, also found in Ozempic and Wegovy, faces increasing competition in obesity and diabetes markets. Meanwhile, semaglutide is being tested for various conditions, including alcohol addiction and chronic kidney disease.
Nov 23, 2025
Risdiplam has lost its patent protection. What are the next steps? - The Hindu
A Delhi High Court ruling has allowed NATCO Pharma Ltd to produce a generic version of Risdiplam, a drug for spinal muscular atrophy, previously patented by Hoffmann-La Roche AG. This decision, which prioritizes public interest, enables NATCO to sell the drug at ₹15,900 per bottle, significantly lower than Roche's price of over ₹6 lakh, improving access for Indian patients with rare diseases.
Nov 23, 2025
Nationwide Operation Targets Illegal Drug Trade: Cough Syrups and Opioids Confiscated in Coordinated Raids Across Multiple States
In a nationwide crackdown, Indian authorities have dismantled illegal networks distributing banned opioids and codeine-laced cough syrups. The multi-state raids targeted various locations, including student campuses and smuggling routes, highlighting the ongoing battle against the illegal drug trade.
Nov 23, 2025
Medications for Weight Loss, Cancer, Diabetes, and Heart Conditions to be Provided to Armed Forces and ESIC Hospitals
The Indian government is set to issue global tenders for high-cost patented drugs, including weight-loss, cancer, diabetes, and cardiac medications, to ensure a steady supply to armed forces and ESIC hospitals. This initiative, led by the Union Health Ministry and Department of Pharmaceuticals, marks a significant policy shift in healthcare procurement.
Nov 23, 2025
India's pharmaceutical exports approaching $30 billion, according to DrugsControl Media Services.
India's pharmaceutical exports are approaching $30 billion, according to a report by EY Parthenon and the Organisation of Pharmaceutical Producers of India (OPPI). The report highlights the role of partnerships and digital-first strategies in driving the growth of Indian pharma on a global scale.
